Attention-deficit hyperactivity disorder historical perspective: Difference between revisions
| Line 8: | Line 8: | ||
==Historical Perspective== | ==Historical Perspective== | ||
===Discovery=== | ===Discovery=== | ||
One of the earliest recorded mentions of a disorder resembling our modern conception of ADHD comes from “On Attention and its Diseases,” a book published in 1798 by Scottish physician Sir Alexander Crichton. In his book, Crichton spoke of a disorder characterized by an “incapacity of attending with a necessary degree of constancy to any one object.”<ref name="ADHD History #4"></ref> | |||
In | |||
===Development of Treatment Strategies=== | ===Development of Treatment Strategies=== | ||
Revision as of 14:41, 4 August 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2]
|
Attention-deficit hyperactivity disorder Microchapters |
|
Differentiating Attention-Deficit Hyperactivity Disorder from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Template:Attention-deficit hyperactivity disorder On the Web |
|
American Roentgen Ray Society Images of Attention-deficit hyperactivity disorder historical perspective |
|
FDA on Attention-deficit hyperactivity disorder historical perspective |
|
CDC on Attention-deficit hyperactivity disorder historical perspective |
|
Attention-deficit hyperactivity disorder historical perspective in the news |
|
Blogs on Attention-deficit hyperactivity disorder historical perspective |
|
Directions to Hospitals Treating Attention-deficit hyperactivity disorder |
Overview
ADHD symptoms have been recognized in children and described in medical texts since the nineteenth century, though the formal diagnosis had not yet been devised. ADHD was first included in some form in the DSM in its second edition, when it was referred to as “hyperkinetic reaction of childhood.” It was not until the third edition of the DSM was released in 1980 that the disorder was formally identified as “ADD (Attention-Deficit Disorder) with or without hyperactivity.” The use of medications to treat the disorder was first brought to attention in 1937 by Rhode Island physician Dr. Charles Bradley. Since that time, the prescription of stimulants has become a first-line treatment for ADHD.[1]
Historical Perspective
Discovery
One of the earliest recorded mentions of a disorder resembling our modern conception of ADHD comes from “On Attention and its Diseases,” a book published in 1798 by Scottish physician Sir Alexander Crichton. In his book, Crichton spoke of a disorder characterized by an “incapacity of attending with a necessary degree of constancy to any one object.”[1]
Development of Treatment Strategies
In 1937, a Dr. Bradley in Providence, RI reported that a group of children with behavioral problems improved after being treated with stimulant medication. In 1957, the stimulant methylphenidate (Ritalin), which was first produced in 1950) became available under various names (including Focalin, Concerta, Metadate, and Methylin); it remains one of the most widely prescribed medications for ADHD. Initially the drug was used to treat narcolepsy, chronic fatigue, depression, and to counter the sedating effects of other medications. The drug began to be used for ADHD in the 1960s and steadily rose in use.
In 1975, Pemoline (Cylert) was approved by the FDA for use in the treatment of ADHD. While an effective agent for managing the symptoms, the development of liver failure in 14 cases over the next 27 years would result in the manufacturer withdrawing this medication from the market. New delivery systems for medications were invented in 1999 that eliminated the need for multiple doses across the day or taking medication at school. These new systems include pellets of medication coated with various time-release substances to permit medications to dissolve hourly across an 8–12 hour period (Medadate CD, Adderall XR, Focalin XR) and an osmotic pump that extrudes a liquid methylphenidate sludge across an 8–12 hour period after ingestion (Concerta).
In 2003, Atomoxetine (Strattera) received the first FDA approval for a nonstimulant drug to be used specifically for ADHD. In 2007 Lisdexamfetamine becomes the first prodrug to receive FDA approval for ADHD. The landmark study of 1999 – The largest study of treatment for ADHD in history – is published in the American Journal of Psychiatry. Known as the Multimodal Treatment Study of ADHD (MTA Study), it involved more than 570 children with ADHD at 6 sites in the United States and Canada randomly assigned to 4 treatment groups. Results generally showed that medication alone was more effective than psychosocial treatments alone, but that their combination was beneficial for some subsets of ADHD children beyond the improvement achieved only by medication. More than 40 studies have subsequently been published from this massive dataset.
Impact on Cultural History
In 1918–19, the world-wide influenza pandemic left many survivors with encephalitis, affecting their neurological functions. Some of these exhibited immediate behavioral problems which may correspond to ADHD (although no diagnosis for such a disorder existed at the time). This caused many later commentators to believe that the condition was the result of injury rather than heredity. (The concept of hyperactivity not being caused by brain damage was first described by Stella Chess as, ""Hyperactive Child Syndrome" in 1960.[2]) This caused a significant rift in the understanding of the disorder. Europeans saw hyperkinesis as unusual and often associated it with mental retardation, brain damage, and conduct disorder, and changes to the ICD were not made until 1994. In the USA by 1966, following observations that the condition existed without any objectively observed pathological disorder or injury, researchers changed the terminology from Minimal Brain Damage to Minimal Brain Dysfunction. A study by two anthropologists looked at the way laypersons talk about ADHD, and found five thematic patterns: "(1) appropriating the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) descriptors; (2) schools as identity-construction sites; (3) resistance: biology versus moral culpability; (4) alternative solutions to a real problem; and (5) relief and hope in naming experience."[3]
Famous Cases
Many famous people have shared their experiences after being diagnosed with ADHD. Such celebrities include Terry Bradshaw, Richard Branson, Jim Carrey, James Carville, Ryan Gosling, Woody Harrelson, Michael Phelps, and Solange Knowles.[4]
References
- ↑ 1.0 1.1 Lange, K. W., Reichl, S., Lange, K. M., Tucha, L., & Tucha, O. (2010). The history of attention deficit hyperactivity disorder. Attention Deficit and Hyperactivity Disorders, 2(4), 241–255. http://doi.org/10.1007/s12402-010-0045-8.
- ↑ Classification of ADHD through History. Retrieved on 2006-09-15.
- ↑ Danforth, Scot (2001). "Hyper Talk: Sampling the Social Construction of ADHD in Everyday Language". Anthropology & Education Quarterly. 32 (2): 167–190. Retrieved 2008-04-07. Unknown parameter
|coauthors=ignored (help) - ↑ “Famous People with ADHD.” (2016). Adult Attention Deficit Disorder Center of Maryland.